Supplier News Breaks Archives
PE treatment to be distributed by pharmacy cooperative
June 14th, 2013
HUNTINGTON BEACH, Calif. – Absorption Pharmaceuticals has entered a distribution agreement with the Independent Pharmacy Cooperative (IPC) in which its topical treatment for premature ejaculation, Promescent, will be made available to IPC's more than 4,500 member pharmacies nationwide.
IPC is now stocking Promescent at its two distribution centers and making member pharmacies aware of the Promescent's availability, Absorption Pharmaceuticals said Friday.
A topical spray, Promescent is applied to the penis 10 minutes before sex, enabling a man to attain ejaculation control. The spray's unique eutectic mixture allows for effective absorption of topical lidocaine, the company noted. Use of a condom isn't required. The spray absorbs and dries in just a few minutes and can be easily washed off before intercourse so that transmission isn't an issue. The reduced sensitivity typically lasts at least 30 minutes to more than one hour, depending upon the dose and penis sensitivity.
Developed with a leading U.S. university's school of pharmacy, Promescent's absorption technology, in conjunction with the metered-dose spray bottle, enables men to deliver a specific and reproducible amount of lidocaine through the stratum corneum of the penile skin to the dermis and control ejaculation latency, according to Absorption Pharmaceuticals. Promescent allows men to easily manage penile sensitivity in order to maintain optimum sexual satisfaction.
The company added that Promescent is becoming first-line therapy for premature ejaculation (PE) at many urologists and Large Urology Groups Practice Association (LUGPA) members, replacing off-label medications which have known side effects. Promescent is available over the counter by way of FDA monograph 21 CFR 348.10 and has minimal risk of systemic side effects.
The effectiveness, ease of use, safety and low cost per dose of the medication are key reasons for Promescent's rise in popularity among physicians, Absorption Pharmaceuticals said.
"Urologists want their patients to have convenient and private locations for obtaining Promescent after their office visit," stated Jeff Abraham, chief executive officer of Absorption Pharmaceuticals. "The relationship with IPC now gives patients in virtually every location in the country the fast and confidential access to what has become a mainstream medication for PE."
The company noted that many independent pharmacies provide compounding services such as Trimix for erectile dysfunction (ED), and some urologists who prescribe Trimix and other injection therapies for ED are recommending Promescent to those patients in order to achieve a better overall sexual experience.
"We have witnessed a steady growth in product demand since our first member pharmacy started carrying Promescent, " commented Dean Slaugenhoup, director of contracts and purchasing at IPC. "Our mission at IPC is to provide our members cost-effective and convenient access to products that have passed a threshold of acceptance by physicians, and Promescent is now clearly in this category. It was time to formalize the relationship."